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ProtectionLymphocytes of the diffuse nasal-associated lymphoid tissue (d-NALT) are uniquely positioned to tackle
respiratory pathogens at their point-of-entry, yet are rarely examined after intranasal (i.n.) vaccinations or
infections. Here we evaluate an i.n. inoculation with Sendai virus (SeV) for elicitation of virus-speciﬁc
antibody forming cells (AFCs) and CD8+ T cells in the d-NALT. Virus-speciﬁc AFCs and CD8+ T cells each
appeared by day 7 after SeV inoculation and persisted for 8 months, explaining the long-sustained protection
against respiratory virus challenge conferred by this vaccine. AFCs produced IgM, IgG1, IgG2a, IgG2b and IgA,
while CD8+ T cells were cytolytic and produced low levels of cytokines. Phenotypic analyses of virus-speciﬁc
T cells revealed striking similarities with pathogen-speciﬁc immune responses in the intestine, highlighting
some key features of adaptive immunity at a mucosal site.Diseases, St. Jude Children's
, TN 38105, USA. Fax: +1 901
tz).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Human parainﬂuenza virus type 1 (hPIV-1) is a serious pathogen
of humans and causes infections which can range in severity from
mild (e.g. rhinorrhoea and laryngitis) to severe (e.g. laryngotracheo-
bronchitis). hPIV-1 infections result in approximately 50,000 pediatric
hospitalizations per year in the US alone (Vainionpaa and Hyypia,
1994; Henrickson et al., 2004), with a rate of infection among immune
compromised individuals exceeding that of healthy individuals by
three-fold (Henrickson et al., 2004; Sato andWright, 2008). Currently
there is no licensed vaccine for hPIV-1.
Sendai virus (SeV), a natural pathogen of mice (Faisca and
Desmecht, 2007) is endemic in many parts of the world, yet there
have been no conﬁrmed reports of SeV-mediated disease in humans.
Based on sequence homology SeV is closely related to hPIV-1(McCarthy and Goodman, 2010; Power et al., 1992; Gorman et al.,
1990; Lyn et al., 1991). The two viruses are also well related in terms
of B and T cell cross-reactivities (Dave et al., 1994; Smith et al., 1994).
SeV has been recently tested as a xenotropic vaccine for hPIV-1 and as
a vector for expression of genes from other serious pathogens
including respiratory syncytial virus (RSV)(Slobod et al., 2004; Zhan
et al., 2008, 2007; Jones et al., 2009; Takimoto et al., 2004, 2005). In
the cotton rat model, recombinant SeVs have been shown to protect
against RSV, hPIV-1, hPIV-2 and hPIV-3 (Jones et al., 2009). The
protection appears early and can persist for the lifetime of an animal
(Jones et al., 2009). Clinical studies have also been conducted with
unmodiﬁed SeV showing that the vaccine is well tolerated in adults
(Slobod et al., 2004) and toddlers (data not shown).
The correlates of protection for respiratory infections are complex. In
general, vaccine-induced antibody provides a ﬁrst line of defense by
neutralizing virus, opsonizing virus for attack by other effectors, and
supporting antibody-dependent cell-mediated cytotoxicity (ADCC).
CD8+ T cells also play a key role by recognizing and killing virally-
infected targets (Kast et al., 1991). In the case of viral respiratory
infections, the B and T cell responses of the d-NALTmay be of particular
importance as these cells are positioned as ﬁrst defenders against virus
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430 R. Rudraraju et al. / Virology 410 (2011) 429–436at its point-of-entry. Despite their opportune location, d-NALT cells have
been studied only rarely during vaccine evaluations (Wiley et al., 2001;
Liang et al., 2001; Singleton et al., 2003). The current studywasdesigned
to examine both antibody forming cells (AFCs) and CD8+ T cells of the
murine d-NALT following an i.n. inoculation with SeV. The results
demonstrate that a single i.n. inoculation with SeV-induced durable d-
NALT-resident AFCs and CD8+ T cell activity. The characteristics of these
responses were highly reminiscent of pathogen-speciﬁc immune
responses of the gut.
Results
Rapid recruitment and long-term persistence of SeV- speciﬁc AFCs in the
d-NALT
To evaluate the kinetics and persistence of respiratory tract
immune responses toward SeV, we inoculated C57BL/6 mice with a
single i.n. dose of virus (250 PFU). AFCs with reactivity toward SeV
were then evaluated from 1 week to 8 months post-vaccination.
Groups of mice were sacriﬁced at each time point for the collection of
d-NALT, lungs and BAL. Signiﬁcant numbers of virus-speciﬁc AFCs,
inclusive of IgM, IgG and IgA-producing cells (IgAN IgG or IgM) were
observed in the d-NALT as early as day 7 and throughout the course of
analysis (Fig. 1A). When a battery of IgG subclasses were examined at
the peak of activity (month 1), subtypes IgG1, IgG2a, and IgG2b were
scored (Fig. 1A inset). AFCsweremore prevalent in the d-NALT than in
the lungs (Fig. 1B) and very few AFCs were observed in the BAL
(Fig. 1C) or in the nasal wash (data not shown).
To determine if the SeV-speciﬁc antibodies secreted by d-NALT
AFCs might correlate with free antibodies in the upper airways, we
examined SeV-speciﬁc IgG and IgA antibodies in the nasal wash. Both
isotypes were evident (Fig. 1D). Antibodies were present for as long as
8 months (although absolute titers varied) despite some reduction in
AFC numbers at the end of the time course (Fig. 1A). Experiments
were curtailed at 8 months to avoid the morbidity and mortality
associated with aged animals. IgG/IgA ratios were higher for free
antibodies than for AFCs, perhaps reﬂecting the fact that IgA may be
tethered to the airways by secretory component and may be difﬁcult
to capture by nasal wash.
Antigen-speciﬁc CD8+ cells appear in the d-NALT in response to SeV
The T cell response to SeV inoculation in C57BL/6 mice is dominated
by CD8+ T cells speciﬁc for an immunodominant epitope in the viral
nucleoprotein (NP324–332/Kb (Cole et al., 1994a)). Analysis of SeV-
inoculated mice revealed the rapid recruitment of the CD8+NP324–332/
Kb-speciﬁc T cells in theupper and lower respiratory tract (URTand LRT)
by day 7 (Fig. 2). The percentages of CD8+NP324–332/Kb-speciﬁc T cells
were much higher than SeV-speciﬁc AFCs. While AFCs were detected
at levels of b1% among total lymphocytes in the d-NALT (Fig. 1),
CD8+NP324–332/Kb-speciﬁc T cells exceeded 10% on day 10. BAL
harbored even greater percentages of CD8+NP324–332/Kb-speciﬁc T
cells onday10. TheT cellswere also detected in thenasalwash, reaching
percentages as high as 25% among lymphocytes at peak activity (data
not shown; total lymphocyte numbers in the nasal washwere too small
for comprehensive analyses). Examination of the organized NALT
(o-NALT) was precluded by the very small size of o-NALT tissues in
the adult mouse. Cervical lymph nodes (CLN) were examined, but theFig. 1.AFCs are rapidly recruited and persistentlymaintained in the d-NALT following SeV
vaccination. AFCs were measured in C57BL/6 mice after a single i.n. inoculation with 250
PFU Sendai virus, on day 7, day 10, month 1, month 3 andmonth 8. IgM, IgG and IgA AFCs
were monitored in the d-NALT, lungs and BAL (panels A, B, and C, respectively). At peak
activity, d-NALT cellswere also assessed for IgG1, IgG2a, IgG2b and IgG3production (panel
A inset). For BAL samplings, due to limited cell numbers, AFCs were examined on day 7
(IgM and IgA only), day 10 (IgM, IgG and IgA), month 1 (IgG and IgA only), and month 3
(IgM, IgG and IgA). Nasal wash IgG and IgA isotypes were measured by ELISA (panel D).frequencies of CD8+NP324–332/Kb-speciﬁc T cells in the CLN were
variable and often less than 1% on day 10. Of interest, the percentages of
CD8+NP324–332/Kb-speciﬁc T cells in the d-NALT exceeded thoseof otherDa
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Fig. 2. Rapid and durable appearance of CD8+NP324–332/Kb-speciﬁc T cells in the d-NALT
after SeV inoculation. The percentages of CD8+NP324–332/Kb-speciﬁc T cells in the d-NALT,
lungs and BAL of C57BL/6mice inoculatedwith 250 PFU SeVweremeasured on day 7, day
10, month 1, month 3 and month 8.
Fig. 3.Phenotypic analyses of d-NALT cells. After inoculation of C57BL/6micewith 250 PFU SeV,
and on CD8+ cells. NP324–332/Kb-speciﬁc T cells were then analyzed for markers CD62L, CD44, C
Circles highlight the major CD8+ NP324–332/Kb-speciﬁc T cell populations at day 10, month 1, m
431R. Rudraraju et al. / Virology 410 (2011) 429–436samples (BAL, lungs, and nasal wash) at the latest tested time point
(Fig. 2). Clearly, persistence typiﬁed lymphocytes of the d-NALT for both
AFC and T cell populations.A change in phenotype among NP324–332/K
b-speciﬁc T cells in the d-NALT
between day 10 and month 1
The expression of CD62L, CD44, CD11a, CD103 and CD69 were
evaluated on CD8+NP324–332/Kb-speciﬁc T cells in the d-NALT between
day10 andmonth8. As shown in Fig. 3, day 10CD8+NP324–332/Kb-speciﬁc
T cells were predominantly CD62LLoCD44HiCD11aHiCD103LoCD69Int.
By month 1 there was an increase in CD103 and CD69 expression
and a marginal decrease in CD44 expression, rendering most cells
CD62LLoCD44IntCD11aHiCD103HiCD69Hi. The cells maintained this pheno-
type throughout the 8 month time course of analyses.d-NALT cellswere collected for T cell phenotype analyses. Cellswere gated on lymphocytes
D11a, CD103 and CD69. Test days included day 0, day 10, month 1, month 3 andmonth 8.
onth 3, and month 8, being of phenotype CD62LLoCD11aHiCD103HiCD69Hi.
432 R. Rudraraju et al. / Virology 410 (2011) 429–436Virus-speciﬁc CTLs in the d-NALT of SeV primed mice
To investigate the functional capacity of the d-NALT T lympho-
cytes, we examined cytolytic activity by 51Cr-release assay with
NP324–332 pulsed L929-Kb target cells. Assays were conducted on day
10, the time of peak NP324–332/Kb-speciﬁc T cell percentages. Cells
from the d-NALT were clearly cytotoxic as demonstrated in Fig. 4,
although responses were slightly weaker than those of the lower
respiratory tract. Bymonth 1, cytolytic activity wasmuch reduced and
was detected inconsistently between experiments (data not shown).
Cytokine responses following SeV inoculations
Intracellular cytokine assays were conducted to deﬁne the capacity
of NP324–332/Kb-speciﬁc T cells to produce cytokines on day 10. These
studies were performed with and without the addition of the NP324–332
peptide. As shown in Fig. 5, IFN-γ and TNF-α were produced
predominantly by CD8+ T cells of the BAL. Responses were weaker in
the lung and again weaker in the d-NALT. For example, approximately
22% of the peptide-stimulated CD8+ T cells of the BAL produced IFN-γ,
whereas the percentagewas approximately 5% in the lung and 2% in the
d-NALT. Activities did not improve when antigen presenting cells were
added to cultures or when collagenase was omitted from the cell
isolation method (data not shown). Other cytokines (IL-2, IL-4, IL-5
IL-10, IL-13, and IL-17) were also tested, but for these, there was little
difference between test and control wells (with and without NP324–332
peptide).
We also measured the concentrations of free cytokines in the nasal
wash and BAL. Low levels of IFN-γ and TNF-α were measured in the
nasal wash as compared to the BAL (Fig. 6), consistent with data from
the intracellular cytokine assays (Fig. 5). There was also weak IL-5
activity in the BALwhile levels of IL-2, IL-4, IL-10, IL-13 and IL17awere
below detection.
Discussion
Preclinical studies have previously demonstrated the protective
efﬁcacy of SeV against hPIV-1 in both cotton rats and African green
monkeys (Jones et al., 2009; Zhan et al., 2008; Hurwitz et al., 1997).
Research has also indicated the safety of SeV in clinical trials (Slobod
et al., 2004). To better understand the immune correlates of
protection for this vaccine, we have employed a well-characterized
murine system for evaluation of the AFCs and T cell activities in the
d-NALT. Data show that after a single i.n. inoculation of C57BL/6 mice0.125 0.25 0.5 1 2 4 8 16
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Fig. 4. Cells of the d-NALT are cytolytic. Lymphocytes from d-NALT, lungs and BAL were
tested for cytotoxicity on day 10. Results from assays with NP324–332-pulsed and
unpulsed cells are shown. Effectors were serially diluted (1:2) to test six E:T ratios
beginning at 12.5:1.with SeV, the d-NALT is quickly populated with virus-speciﬁc AFCs
and CD8+NP324–332/Kb-speciﬁc T cells. Both of these lymphocyte
populations appear by day 7 and persist for the lifetime of the animals,
and both are found at greater percentages in the d-NALT than in the
lungs and BAL at 8 months post-vaccination. These d-NALT lympho-
cytes are well positioned to inhibit virus at its point-of-entry and may
therefore be the most inﬂuential gatekeepers for long-term virus
control.
Our study of d-NALT lymphocytes responsive to a respiratory
pathogen revealed a striking similarity between immune responses of
the d-NALT and gut. Indeed, a common mucosal immune system has
been previously described which predicts some of these similarities
(Lazarus et al., 2003). An obvious similarity is the relatively high
numbers of IgA-producing AFCs in the d-NALT and signiﬁcant IgA
titers in nasal washes (Kawanishi et al., 1983; Mora et al., 2006;
Takahashi et al., 2009; Mora and Von Andrian, 2008; Masopust et al.,
2001).We note that in the d-NALT, IgGs of multiple sub-isotypes were
also produced inclusive of IgG1, IgG2a and IgG2b. While IgA is best
suited for deposition at mucosal surfaces via poly-Ig assisted
transcytosis, IgGs may also facilitate viral clearance by mediating a
spectrum of functions including complement ﬁxation, neutralization,
and ADCC (Murphy et al., 2008), all of whichmay reduce the spread of
virus and virus-infected cells.
Our analysis of the CD8+ T cell population revealed that virus-
speciﬁc T cells expressed a predominantly CD62LLoCD103Lo and
CD44Hi phenotype on day 10 and transitioned to a predominantly
CD62LLoCD103HiCD44Int phenotype after 1 month. The shift in
phenotype revealed an additional similarity between d-NALT and
gut-associated immune activities (Masopust et al., 2001, 2004; Kim
et al., 1999). As an example, a study by Kim et al. examined intestinal
intraepithelial lymphocytes (IELs) following the activation of adop-
tively transferred transgenic Ova-speciﬁc CD8+ T cells with Vesicular
stomatitis virus (VSV)-Ova. Four days post- challenge, the CD8+ T
cells that had trafﬁcked to the intestinal epithelium were predomi-
nantly CD62LLoCD103Lo and CD44Hi. By day 38, the cells maintained
the CD62LLo phenotype, but had shifted to CD103HiCD44Int expression
(Kim et al., 1999). The relevance of CD103 to mucosal immunity
relates to its binding to the epithelial cell-speciﬁc marker e-cathedrin.
In CD103 KO mice there is a deﬁciency in mucosal T cell numbers in
the intestinal epithelium, yet the requirement for CD103 as amediator
of T cell migration and retention in the intestine is not absolute (Schon
et al., 1999; Lefrancois et al., 1999; Gorfu et al., 2009). Takamura et al.
have further shown that when SeV-speciﬁc memory cells are
adoptively transferred into a naïve mouse and re-challenged, they
trafﬁc to the lower respiratory tract and upregulate CD103 (Takamura
et al., 2010). Notwithstanding, the maintenance of the CD103Hi
phenotype is more striking in the d-NALT and intestinal IEL than in the
lungs or BAL (Kohlmeier et al., 2007; Masopust et al., 2004). The
CD44Int phenotype is also more pronounced in the d-NALT and
intestinal IEL than in the LRT (Hogan et al., 2001), possibly deﬁning a
cell with an attenuated contraction phase but poised for immediate
recall upon virus challenge (Khanolkar et al., 2004).
Another feature shared between d-NALT and intestine was the
CD69Hi phenotype. This marker is often upregulated upon acute
activation, but then subsides. In our study, the majority of d-NALT
cells were CD69Hi at 1 and 3 month time points. Masopust et al. have
found that intestinal IELs are also close to 100% CD69Hi 3 months
following a VSV infection (Masopust et al., 2004). This marker is more
pronounced in intestinal IEL than in lung-resident VSV-speciﬁc cells
(Masopust et al., 2004) or in populations of NP324–332/Kb-speciﬁc T
cells in lungs and BAL 1 month after an SeV inoculation (the latter are
CD69Hi at the 70% level (Hogan et al., 2001; Kohlmeier et al., 2007)).
Possibly, the maintenance of the CD69Hi phenotype among the
majority of d-NALT and intestinal IEL CD8+ T cells reﬂects long-
term antigen deposition in affected tissues, which in turn assists the
maintenance of virus-speciﬁc lymphocytes in the mucosa.
Fig. 5. Cytokine expression by d-NALT, lung and BAL cells following peptide stimulation. Ten days post-SeV inoculation of C57BL/6 mice, d-NALT, lungs and BAL cells were isolated for measurement of intracellular cytokine production. Results
for cytokines IFN-γ and TNF-α are shown, as these were detected at signiﬁcant levels.
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Fig. 6. Free cytokine in the respiratory tract of animals exposed to SeV. Nasal wash and
BAL samples were tested for the presence of free cytokines over the course of a 1 month
period. Results for cytokines IFN-γ, TNF-α and IL-5 are shown, as these were detected at
signiﬁcant levels.
434 R. Rudraraju et al. / Virology 410 (2011) 429–436Questions concerning antigen deposition and lymphocyte persis-
tence have been a topic of much debate. Some experiments suggest
that long-term antigen deposition is instrumental in lymphocyte
persistence, while other experiments reveal that lymphocyte persis-
tence can be maintained even when receptor-antigen interactions are
blocked (Takamura et al., 2010; Gray, 2002; Mullbacher, 1994;
Maruyama et al., 2000; Gray, 1993). Experiments are warranted to
further dissect mechanisms responsible for the impressive durability
of SeV-induced lymphocyte responses. A future analysis of immuno-
dominant CD4+ T cell populations is also warranted (Cole et al.,
1994b; Zhong et al., 2000; Cauley et al., 2002) to determine if/how
d-NALT B and CD8+ T cells are affected by CD4+ T cell activities.
Results may better explain how SeV-based vaccines, like some other
live viral vaccines, can confer B cell function, T cell function and
protective immunity for the lifetime of the animal (Jones et al., 2009;
Slifka and Ahmed, 1996; Slifka et al., 1998; Crotty et al., 2003; Amanna
et al., 2006; Hurwitz et al., 1997).
The CD11aHi T cell phenotype was one additional characteristic
shared by the majority of d-NALT and intestinal IELs (Masopust et al.,
2001). CD11a is both an adhesion and activation marker that is
involved in the extravasation of cells from the circulation. The
blockade of CD11a can impair T cell adhesion to endothelial cells
and retention of cells in the lungs, as demonstrated by inhibition
studies with CD11a-speciﬁc antibodies (Thatte et al., 2003). In the
LRT, CD11a expression is mixed; 1 month following SeV inoculation,
cells in the BAL and lungs are 30–40% and 90–100% CD11aHi,
respectively (Ely et al., 2003, 2006). Cells which have down-regulated
CD11a are not terminally differentiated, as upon transfer to naïve
mice and re-challenge, they return to the airways, and regain CD11aHi
expression levels (Ely et al., 2003).
A ﬁnal comparison revealed similarities between T cell functions of
the d-NALT and intestinal lymphocytes in terms of cytotoxicity and
IFN-γ cytokine expression (albeit IFN-γ was expressed at low levels
among d-NALT T cells) (Kim et al., 1999; Masopust et al., 2001;
Lefrancois et al., 1999; MacDonald, 1999). In each case, cell numbersand their associated functional capacities dropped with time
(Masopust et al., 2001). Masopust et. al. and Kim et. al. have suggested
that the overall phenotype/function of the intestinal memory T cell
depicts a cell that: (i) remains in the mucosa for long periods, (ii)
modiﬁes its phenotype while tissue-resident, and (iii) may not be part
of the recirculating CD8+ T memory pool (Masopust et al., 2004; Kim
et al., 1999). Despite the gradual drop in numbers and function with
time (Masopust et al., 2001), intestinal T cells are capable of rapid
recall (Kim et al., 1999).
In conclusion, data from AFC and CD8+ T cell analyses identify the
d-NALT as an important site for immune surveillance following a
single inoculation with SeV. Unique AFC and T cell features typify
immune responses of the intestinal mucosa. Possibly, these features
assist the long-term- maintenance of d-NALT lymphocytes in a
position opportune for tackling respiratory virus at its point-of-entry.
Materials and methods
Animals and inoculations
Female C57BL/6J (B6; H2b) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Animals were housed under speciﬁc
pathogen-free conditions in a biosafety level 2+ containment area at
the St. Judes animal facility, as speciﬁed by the Association for
Assessment and Accreditation for Laboratory Animal Care (AAALAC)
guidelines. At the time of live virus challenge, mice anesthetized with
Avertin were inoculated i.n. with 250 plaque forming units (PFU) of
SeV, Enders strain. Mice were approximately 2 months of age at the
initiation of the immunization protocols. Experiments were con-
ducted in replicate with 4–10 animals per group in each experiment.
Sentinel mice were routinely housed in racks with test mice to
validate biocontainment practices and to ensure no inadvertent
animal infections with SeV.
Preparation of samples
Immediately prior to sacriﬁce, mice were anesthetized with
avertin and exsanguinated. Nasal wash samples were obtained from
sacriﬁced animals by exposing the trachea and washing the upper
trachea and nasal cavity with 200 μl of PBS. Bronchoalveolar lavage
(BAL) samples were collected by inserting catheters into trachea and
washing three times with 1 ml PBS (3 ml total). Wash samples were
centrifuged to separate cellular material. d-NALT (Davis, 2001;
Asanuma et al., 1997) was harvested by removing skin, lower jaws,
soft palates (including the attached o-NALT), muscles, cheek bones
and incisors from the heads. Remaining snouts were cut into small
pieces, after which the cells were released by digestion with 4 mg/ml
collagenase in PBS at 37 °C for 30 min (the collagenase treatment was
omitted from studies in which panels of membrane markers were
tested). The cells were ﬁrst washed with PBS and then suspended in
PBS or complete tumour medium (CTM), a Modiﬁed Eagles Medium
(Invitrogen, Grand Island, NY) supplemented with dextrose (500 μg/
ml), glutamine (2 mM), 2-mercaptoethanol (3×10−5 M), essential
and non-essential amino acids, sodium pyruvate, sodium bicarbonate
and antibiotics (Woodland et al., 1990; Kappler et al., 1981),
containing 10% heat inactivated fetal bovine serum (FBS) and layered
onto a 40/75% discontinuous percoll gradient. After centrifugation at
1,000×g for 30 min, the cells were collected from the gradient
interface. The cells were washed 2× in PBS and suspended in CTM
containing 10% heat inactivated FBS. The lungs were perfused with
PBS through the heart to remove blood, suspended and similarly
processed by collagenase digestion and puriﬁcation on percoll
gradients. For antibody ELISAs and free cytokine experiments,
individual mouse samples were tested. For AFC, cytotoxic T cell and
ﬂow cytometry studies, mouse samples from each group were pooled
prior to testing to ensure sufﬁcient cell numbers for assay completion.
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For the detection of SeV-speciﬁc antibodies, sucrose-gradient-puriﬁed
SeV was lysed in disruption buffer (0.05% TritonX-100, 60 mM KCl,
10 mM Tris pH7.8) and dilutedwith PBS to yield 10 μg/ml for the coating
of 96-well ELISA plates (PRO-BINDTM, BD Falcon, Franklin Lakes, NJ). After
overnight incubationwith 50 μl of the diluted virus lysate perwell at 4 °C,
plates were washed 3× with PBS and blocked with 200 μl of PBS
containing 3% bovine serum albumin (BSA, Sigma, St Louis, MO). Nasal
washes from vaccinated and control animals were serially diluted in PBS
containing 1% BSA and 0.1% Tween 20. 50 μl of the diluted samples were
applied to the plates and incubated for 1 h at 37 °C. Plates were then
washed 6× with PBS-Tween 20 (0.05%) and incubated with alkaline
phosphatase-conjugated goat anti-mouse IgM (Cat #1020-04, Southern
Biotechnologies Assoc, Birmingham, AL), IgG (Cat #1030-04) or IgA (Cat
#1040-04) diluted 1:1000 in PBS containing 1% BSA and 0.1% Tween 20,
for 1 hr at 37 °C. Plates were washed 6×with PBS-Tween 20 (0.05%) and
developed by addition of p-nitrophenyl phosphate substrate (0.5 mg/ml)
in diethanolamine buffer (0.1 M TRIS, 0.1 M NaCl. 5% Diethanolamine,
10 mMMgCl2, pH 9.8). The reactionwas stopped after 20 minwith 5 μl of
0.5 M EDTA (Cat# E-7889, Sigma). Assays were read at OD 405 nm (E
max® precision microplate reader, Molecular Devices, Inc, Sunnyvale,
CA). Titerswere determinedusing non-linear regression, one-site binding
software (0.12 OD cut-off, GraphPad Prism, San Diego, CA).
AFC ELISPOT
The ELISPOT plate (multiscreen™-IP, Millipore, Cat#MAIPS4510,
Billerica, MA) was coated with sucrose-gradient-puriﬁed disrupted
SeV overnight at 1 ug/100ul/well overnight at 4 °C. Wells were
washed 4× with PBS and blocked with CTM containing 10% FCS.
1×105 cells were then applied to the wells and incubated for 3 h at
37 °C. After washing plates 3× with PBS and 3× with PBS-Tween 20,
100 ul of alkaline phosphatase-conjugated goat anti-mouse antibo-
dies (see above; also anti-IgG1 (Cat #1070-04), IgG2a (Cat #1080-04),
IgG2b (Cat #1090-04), and IgG3 (1100-04)) in 1% BSA were added to
each well. After overnight incubation at 4 °C, the antibody was
removed and plates were developed with 100 μl 1 mg/ml BCIP/NBT
(Sigma Aldrich, Cat#B5655). The plates were incubated at room
temperature (RT) and monitored for spot appearance. The exposure
was stopped by rinsing plates with water. Plates were dried and spots
were counted using a Nikon dissecting scope.
MHC tetrameric reagents and analyses
MHC class I (Kb) tetramers were generated by folding Sendai virus
NP324–332 (FAPGNYPAL) with heavy and light chains as described
previously (Cole et al., 1994a; Murali-Krishna et al., 1998). Tetramers
were stored as aliquots at 4 °C. Staining with PE-conjugated tetrameric
reagent was for 1 h at RT, followed by staining with anti-CD8 PerCP
Cy-5.5 and ﬂuorescein isothiocyanate-conjugated anti-CD44, anti-
CD62L, anti-CD69, anti-CD103, or anti-CD11a (Pharmingen, San Diego,
CA) on ice for 20 min. Samples were analyzed on a FACSCalibur. Data
were analyzed using Flowjo Version 7.5.5 Software (Tree Star Inc.,
Ashland, OR).
CTL assays
L929-Kb (L-Kb) target cells (Cole et al., 1987; Ostrand-Rosenberg
et al., 1991) were loaded with peptide and Na251CrO4 as described
previously (Cole et al., 1997). Brieﬂy, monolayers of cells in 6-well
plates were incubated with 75 μCi of Na251CrO4 with or without the
NP324–332 peptide (75 μg) per 700 μl serum free medium for one hour.
FBS was then added to 10% ﬁnal concentration and the targets were
incubated overnight. Cells were washed and counted. Serially diluted
effectors were added to 104 target cells in 96-well round-bottomedmicrotiter plates and incubated for approximately 5 h after which
supernatants were removed for measurement in a Cobra Quantum
gamma counter. The percentage of speciﬁc release was calculated
using the formula: (experimental spontaneous)/(maximum sponta-
neous)×100. Maximum release was counted fromwells with Triton®
X-100 (Sigma, Cat#T8787) diluted 1:20. Spontaneous release was
typically b10% of maximum release.Intracellular cytokine staining following peptide stimulation
Cell populations (2–5×105) were suspended in 200 μl of CTMwith
10 μg/ml Brefeldin A and were cultured for 6 h in 96-well U-bottomed
plates in the presence or absence of 1 μg/ml peptide, NP324–332
(Murali-Krishna et al., 1998). After culture, the cells were washed
twice in PBS/Brefeldin A (10 μg/ml), blocked with monoclonal
antibody to CD16/CD32 (FcγIII/II, Pharmingen) and stained with rat
anti-mouse CD8-PerCp Cy5.5 monoclonal antibody (Pharmingen) for
20 min. They were then washed again in PBS/Brefeldin A, ﬁxed in 1%
formaldehyde in PBS for 20 min, washed in PBS, placed in PBS/0.5%
Saponin (Sigma, St Louis, MO) for 10 min, and incubated with
monoclonal antibodies speciﬁc for IFN-γ, IL-2, IL-4, IL-5, IL-17A
(PE-conjugated, Pharmingen), TNF-α (APC-conjugated, Pharmingen),
IL-10 (FITC-conjugated, Ebioscience) or IL-13 (PE-conjugated
Ebioscience). Samples were run on a FACSCalibur. Data were analyzed
with Flowjo Version 7.5.5 Software.Cytokine measurements
Samples were tested for the presence of eight different cytokines
(IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IFN-γ, and TNF-α), using a
Millipore 8-Plex Mouse Cytokine Assay Kit (Millipore Corporation).
Cytokine samples of known concentrations were used to prepare
standard curves. Individual samples were tested in duplicate. Assays
were analyzed using the Luminex 100/200 System (Luminex
Corporation, Austin, TX).Acknowledgments
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